NCT05441059View on ClinicalTrials.gov

Use of Nucala in Severe Asthma

CompletedOBSERVATIONAL

Enrollment

2,100

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2022

Conditions

Asthma Severe Persistent Uncontrolled

Interventions

DRUG

Mepolizumab 100 MG

Treatment with mepolizumab for severe asthma

Trial Locations (1)

8934 AD

Medical Centre Leeuwarden, Leeuwarden

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Frisius Medisch Centrum

OTHER

NCT05441059 - Use of Nucala in Severe Asthma | Biotech Hunter | Biotech Hunter